unknown
Stage
About
Eradivir develops small molecule therapies using their Bispecific Antigenic immuno-Therapy (BAiT™️) technology to target diseased cells and viruses for immune system clearance, focusing on treatments such as influenza.
Explore Eradivir's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.